期刊文献+

糖尿病肾病发病分子机制 被引量:35

Molecular Mechanisms in the Pathogenesis of Diabetic Nephropathy
原文传递
导出
摘要 糖尿病肾病(DN)是高血糖所导致的一种主要的微血管并发症。在全世界糖尿病病人中,糖尿病肾病都有着非常高的发病率和致死率。并且在中国,糖尿病肾病已经成为一种常见的导致末期肾衰竭的因素。由于糖尿病肾病患者不断增多,传统的单纯通过控制血糖来控制糖尿病肾病并没有取得理想的效果,因此临床上迫切需要一些新的治疗方法来控制糖尿病肾病的发生和发展。最近的研究表明肾素-血管紧张素-醛固酮系统(RAAS)、蛋白激酶-C(PKC)、还原型烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶、转化生长因子-β(TGF-β)等都单独的或共同的参与了DN的发生和发展过程。这些通路彼此交叉,十分复杂,因此需要对糖尿病肾病发病分子机制进行全面的综合的理解。这篇文章旨在讨论已发现的与糖尿病肾病密切相关的分子机制以及下调通路。 Diabetic nephropathy (DN) is one of common microvascular complications in diabetes mellitus.DN has a high morbidity and mortality in diabetic patients around the world. And in China, DN is one of common cause of end-stage renal failure. As the number of diabetic patients with nephropathy is increasing yearly, glycemic control as a tradition therapeutic to manage diabetic nephropathy remain unsatisfactory. Some ground-breaking therapeutic options are urgent needed to prevent the development and progression of diabetic nephropathy. Recent studies suggested renin-angiotensin aldosterone system (RAAS), protein kinase C (PKC), nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), transforming growth factorβ (TGF-β), etc. are activated during the course of diabetes mellitus and that these pathways individually or collectively play a role in the induction and progression of diabetic nephropathy. Since these mechanisms are very complicated, a comprehensive understanding of molecular mechanisms involved in the pathogenesis of the disease is necessary. Therefore, the purpose of this paper is to discuss the discovered mechanisms and downstream pathways in the pathogenesis of diabetic nephropathy.
出处 《现代生物医学进展》 CAS 2014年第16期3184-3187,共4页 Progress in Modern Biomedicine
关键词 糖尿病肾病 肾纤维化 靶点 信号通路 Diabetic nephropathy Renal fibrosis Target site Signaling pathway
  • 相关文献

参考文献31

  • 1Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update [J]. Vascular Pharmacology, 2013, 58(4): 259-271.
  • 2Fujihara CK, Noronha IL, Malheiros, et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney [J]. Journal of the American Society of Nephrology : JASN, 2000, 11(2): 283-290.
  • 3Benigni A, Gagliardini E, Remuzzi G. Changes in glomerular perm- selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement [J]. Seminars in nephrology, 2004, 24(2): 131-140.
  • 4Franco M, Martinez F, Quiroz Y, et al. Renal angiotensin II concent- ration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension[J]. Ameficanj ournal of physiology Regulatory, integrative and comparative physiology, 2007, 293(1): R251-256.
  • 5Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation[J]. Clinical andexperimental pharmacology & physiology, 2010, 37(3): 277-282.
  • 6Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-betal and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms [J]. Kidney international, 2006, 69(1): 105-113.
  • 7Kang YS, Lee MH, Song HK, et al. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice [J]. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, 26(4): 1194-1204.
  • 8Osborn JW, Fink GD, Kuroki MT. Neural mechanisms of angiotensin II-salt hypertension: implications for therapies targeting neural control of the splanchnic circulation [J]. Current hypertension reports, 2011, 13(3): 221-228.
  • 9Park HC, Choi HY, Kim BS, et al. Urinary TGF-betal as an indicator of antiproteinuric response to angiotensin II receptor blocker in prote- inuric renal diseases [J]. Biomedicine & pharmacotherapy = Biom- edecine & pharmacotherapie, 2009, 63(9): 672-678.
  • 10袁军,鲁艳芳,陈陶后,曾祥法.丹参对血管紧张素Ⅱ诱导的肾小球系膜细胞表达TGF-β_1,ROS和PAI-1的影响[J].中国中药杂志,2007,32(22):2400-2404. 被引量:38

二级参考文献10

  • 1张悦 ,何立群 ,韩志芬 ,庞惠芳 ,曹和欣 ,朱晓梅 .抗纤灵、丹参、大黄等药物血清对系膜细胞分泌FN和Ⅳ型胶原的影响[J].中国病理生理杂志,2005,21(8):1643-1643. 被引量:10
  • 2Wilson H M, Haites N E, Booth N A. Effect of angiotensin Ⅱ on plasminogen activator inhibitor-1 production by cultured human mesangial cells[ J]. Nephron, 1997,77 : 197.
  • 3Kang D G, Yun Y G, Ryoo J H, et al. Anti - hypertensive effect of water extract of danshen on renovaseular hypertension through inhibition of the renin angiotensin system[ J]. Am J Chin Med, 2002,30:87.
  • 4Hagiwara H, Kaizu K, Uriu K, et al. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models [J]. Thromb Res, 2003,111:301.
  • 5Eddy A A. Plasminogen activator inhibitor-1 and the kidney[ J]. Am J Physiol Renal Physiol, 2002,283 : F209.
  • 6Yokoyama H, Deckert T. Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis[J]. Diabet Med, 1996,13:313.
  • 7Jiang Z, Seo J Y, Ha H, et al. Reactive oxygen species mediate TGF-betal-induced plasminogen activator inhibitor-1 upregulation in mesangial cells [ J ]. Biochem Biophys Res Commun, 2003, 309:961.
  • 8Lee E A, Seo J Y, Jiang Z, et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 upregulation in mesangial cells and in diabetic kidney [ J ]. Kidney Int, 2005,67 : 1762.
  • 9彭佑铭,刘伏友,罗季安,刘瑞洪.丹参及生脉液对阿霉素所致大鼠肾小球硬化的实验性治疗作用[J].湖南医科大学学报,1999,24(4):332-334. 被引量:21
  • 10陶艳艳,刘成海.丹参及其化学成分抗肝纤维化作用机制研究进展[J].中西医结合学报,2004,2(2):145-148. 被引量:79

共引文献37

同被引文献311

引证文献35

二级引证文献338

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部